Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB
[thumbnail of Supplementary Materials] Other (Supplementary Materials)
11MB

Item Type:Article
Title:Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance
Creators Name:Danielli, S.G., Porpiglia, E., De Micheli, A.J., Navarro, N., Zellinger, M.J., Bechtold, I., Kisele, S., Volken, L., Marques, J.G., Kasper, S., Bode, P.K., Henssen, A.G., Gürgen, D., Delattre, O., Surdez, D., Roma, J., Bühlmann, P., Blau, H.M., Wachtel, M. and Schäfer, B.W.
Abstract:Rhabdomyosarcoma (RMS) is a group of pediatric cancers with features of developing skeletal muscle. The cellular hierarchy and mechanisms leading to developmental arrest remain elusive. Here, we combined single-cell RNA sequencing, mass cytometry, and high-content imaging to resolve intratumoral heterogeneity of patient-derived primary RMS cultures. We show that the aggressive alveolar RMS (aRMS) subtype contains plastic muscle stem-like cells and cycling progenitors that drive tumor growth, and a subpopulation of differentiated cells that lost its proliferative potential and correlates with better outcomes. While chemotherapy eliminates cycling progenitors, it enriches aRMS for muscle stem-like cells. We screened for drugs hijacking aRMS toward clinically favorable subpopulations and identified a combination of RAF and MEK inhibitors that potently induces myogenic differentiation and inhibits tumor growth. Overall, our work provides insights into the developmental states underlying aRMS aggressiveness, chemoresistance, and progression and identifies the RAS pathway as a promising therapeutic target.
Keywords:Alveolar Rhabdomyosarcoma, Antineoplastic Agents, Cell Differentiation, Rhabdomyosarcoma, Skeletal Muscle, Tumor Cell Line
Source:Science Advances
ISSN:2375-2548
Publisher:American Association for the Advancement of Science
Volume:9
Number:6
Page Range:eade9238
Date:10 February 2023
Official Publication:https://doi.org/10.1126/sciadv.ade9238
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library